Search

Objective: There is currently a lack of comprehensive studies that provide clear information about the frequency and characteristics of hypersensitivity reactions associated with H1 antihistamines. The aim of our study was to evaluate the subjects with antihistamine drug allergy diagnosed in our clinic and the provocation tests performed on them with alternative agents. Materials and Methods: This retrospective study was carried out at the immunology and allergy clinic in a tertiary hospital. The study population consisted of adults who presented to our allergy clinic between January 1, 2017 and December 31, 2023 with a history of H1 antihistamine drug allergy and underwent alternative H1 antihistamine drug provocation tests, for whom records were accessible. Results: A total of 45 patients were included in the study. The mean age of the patients was 39.75 ± 13.30 years with 34 (75.55%) being female. Regarding the initial allergic reaction history to H1 antihistamine drugs, allergic reactions occurred with pheniramine hydrogen maleate in 17 (37.77%), with levocetirizine dihydrochloride in 9 (20%), with desloratadine in 7 (15.55%), with cetirizine dihydrochloride in 6 (13.33%), with bilastine in 6 (13.33%), with rupatadine fumarate in 3 (6.66%) patients, and with fexofenadine hydrochloride 1 patient (2.22%). Allergic reactions developed in 7 (15.55%) patients during oral provocation tests. Conclusion: In conclusion, caution is advised with H1 antihistamine hypersensitivity. Misinterpreting hypersensitivity symptoms as those of the primary allergic condition may lead to treatment delays or unnecessary escalation, potentially resulting in life-threatening reactions. Additionally, further research is needed to clarify which antihistamines pose higher allergic risks and to guide the selection of alternatives for testing. [ABSTRACT FROM AUTHOR]

Background: The standard therapeutic regimen for idiopathic chronic eosinophilic pneumonia (ICEP) involves the administration of oral corticosteroids (OCS). However, a notable proportion of individuals experience recurrent episodes after the tapering or cessation of OCS during the course of ICEP. There has been a growing interest in exploring alternative treatment modalities for patients with ICEP at heightened risk of relapse. Objective: The aim of this study was to assess the efficacy of mepolizumab at a dose of 100 mg administered every 4 weeks in preventing relapses of ICEP and its impact on the clinical outcomes. Methods: This retrospective clinical observational study used real-world data to assess the impact of mepolizumab on patients diagnosed with ICEP accompanied by severe asthma. Demographic information and clinical characteristics were extracted from medical records. The study examined the effect of mepolizumab on the annual relapse rate, OCS dose, eosinophil count, and respiratory function parameters. Results: All patients included in the study, with a median (range) follow-up period of 19 months (4–40 months), the annual relapse rate decreased from 0.33 to 0 after the initiation mepolizumab. In addition, the maintenance OCS dose, expressed in methylprednisolone equivalents, declined from 4 mg/day to 0 mg/day. A reduction in the blood eosinophil count was observed, alongside a partial improvement in respiratory function test results among the patients. Conclusıon: A dose regimen of 100 mg of mepolizumab administered every 4 weeks emerges as a promising and well-tolerated therapeutic approach for averting relapses of ICEP. [ABSTRACT FROM AUTHOR]